Could a Fatty-Acid drug help kids with rare energy disorder?

NCT ID NCT06340685

Recruiting now Disease control Sponsor: Jirair Krikor Bedoyan Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study is testing a drug called triheptanoin (Dojolvi) in children with pyruvate dehydrogenase complex (PDC) deficiency, a rare genetic condition that affects energy production. The trial will enroll 6 children aged 1 to 18 and look at safety, side effects, and changes in blood markers like lactate. It is an open-label, proof-of-concept study, meaning everyone gets the drug and the main goal is to see if it is safe and worth studying further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

triheptanoin (Dojolvi)

What this could lead to

If it works, this could point toward a treatment option for PDC deficiency, a rare metabolic disorder.

What could go wrong

This is a very small, early-phase study with only 6 participants. It is designed to test safety and biological signals, not to prove effectiveness. The drug may not improve symptoms or could cause side effects like stomach upset.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates